Decentering and Relapse/Recurrence in MBCT for Depression in Adults

Sponsor
University of British Columbia (Other)
Overall Status
Completed
CT.gov ID
NCT05111665
Collaborator
(none)
227
1
3
8.5
26.6

Study Details

Study Description

Brief Summary

Objective: "Decentering" is defined as the ability to observe one's thoughts and feelings as temporary, objective events in the mind, and is increasingly regarded as a candidate mechanism in mindfulness-based interventions. The current study sought to examine the role of decentering, and other related variables, in the efficacy of Mindfulness-based cognitive therapy (MBCT) as compared to two active comparison conditions.

Method: Formerly depressed individuals (N = 227), randomly assigned to MBCT (n = 74), relaxation group therapy (RGT; n = 77) or treatment-as-usual (TAU; n = 76), completed self-report measures of decentering and symptoms of depression at pre-, mid-, and post-treatment, and relapse was assessed at 3, 6, 9, and 12 months, post-treatment.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness-based Cognitive Therapy (MBCT)
  • Behavioral: Relaxation Group Therapy (RGT)
  • Behavioral: Treatment as usual (TAU)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
227 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
The Association Between Decentering and Reductions in Relapse/Recurrence in Mindfulness-Based Cognitive Therapy for Depression in Adults: A Randomized Controlled Trial
Actual Study Start Date :
Feb 14, 2008
Actual Primary Completion Date :
Oct 31, 2008
Actual Study Completion Date :
Oct 31, 2008

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness-based Cognitive Therapy (MBCT)

Remitted depressed participants received eight-weekly, two-hour MBCT sessions (Segal et al., 2013). This program combines MBSR meditation practices (e.g., body scan, mindful stretching, mindfulness of breath/body/sounds/thoughts) with traditional CT techniques (e.g., psychoeducation about depression symptoms and automatic thoughts, exercises designed to demonstrate how the nature of one's thoughts change with one's mood, questioning of automatic thoughts and creating a relapse prevention plan). Finally, participants engaged in a daily meditation practice and homework exercises directed at integrating the application of awareness skills into daily life. Each MBCT group was led by a masters-level clinician who was an active MBCT/Mindfulness-Based Stress Reduction (MBSR) instructor.

Behavioral: Mindfulness-based Cognitive Therapy (MBCT)

Active Comparator: Relaxation Group Therapy (RGT)

The revised edition of the Changeways Relaxation Programme (Paterson, 1997) served as the active control condition to control for non-specific group factors including group participation, expectation of change or therapeutic contact and attention. The rationale was that relaxation can be used to better manage life stressors which precipitate depressive episodes. Participants received eight-weekly, two-hour relaxation training sessions. This group program combines psychoeducation regarding the effects of stress, diaphragmatic breathing, progressive muscle relaxation, passive relaxation and imagery. It also incorporates time for participants to discuss the events of the week to facilitate the supportive aspect of group participation. Finally, participants were asked to engage in daily exercises to practice the various relaxation strategies. Each RGT group was led by a doctoral-level therapist.

Behavioral: Relaxation Group Therapy (RGT)

Placebo Comparator: Treatment as usual (TAU)

Participants randomized to the TAU group were instructed that participants would receive MBCT at the end of the follow-up period and to seek help from their family doctors or other sources as the normally would, should the participants encounter symptomatic deterioration or other difficulties over the course of the study. At the end of the follow-up phase, participants in the TAU and RGT group were offered the opportunity to receive MBCT.

Behavioral: Treatment as usual (TAU)

Outcome Measures

Primary Outcome Measures

  1. Major depressive disorder (MDD) relapse/recurrence - incidence of [12- month post-treatment follow-up]

    Number of participants meeting criteria for relapse/recurrence of MDD during follow-up

  2. Change in major depressive disorder (MDD) relapse/recurrence - time to relapse/recurrence [3-, 6-, 9-, and 12- month post-treatment follow-up]

    Change in relapse/recurrence of MDD (i.e., survival) across follow-up

Secondary Outcome Measures

  1. Change in Beck Depression Inventory - Second Edition total scores [Pre-, mid- (i.e., at week 4 of MBCT), and post-treatment (i.e., after 8 weeks of MBCT)]

    Change in symptoms of depression across MBCT treatment

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • a Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM IV-TR; American Psychiatric Association (APA), diagnosis of major depressive disorder (MDD) without psychotic features, in Full Remission;

  • three or more prior major depressive episodes;

  • age between 18 and 65 years;

  • cognitive reactivity (CR) or mood-activated dysfunctional beliefs score greater than or equal to eight (see assessment procedure below);

  • a score of less than 10 on the Hamilton Rating Scale for Depression (HRSD);

  • minimum of a 10 week period free of psychotropic medication other than stable dosage of antidepressant medication for a minimum of four weeks;

  • fluency in English; An increased cognitive reactivity score of eight points or more and,

  • ability to give informed consent and complete questionnaires unassisted.

Exclusion Criteria:
  • a diagnosis of bipolar disorder (past or present), schizophreniform disorders, substance abuse or dependence (current or within the past six months), borderline or antisocial personality disorder, or neurocognitive disorders;

  • current psychotherapy or counselling more frequently than twice per month;

  • current practice of meditation more than once per week or yoga more than twice per week;

  • electroconvulsive therapy within the past six months; or

  • self-reported ingestion of alcohol or other psychoactive substances within the past 48 hrs.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mark Lau Vancouver British Columbia Canada V6J 5C6

Sponsors and Collaborators

  • University of British Columbia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mark Lau, Principle Investigator, University of British Columbia
ClinicalTrials.gov Identifier:
NCT05111665
Other Study ID Numbers:
  • H07-03046
First Posted:
Nov 8, 2021
Last Update Posted:
Nov 8, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 8, 2021